<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02360878</url>
  </required_header>
  <id_info>
    <org_study_id>DJBS meal test</org_study_id>
    <nct_id>NCT02360878</nct_id>
  </id_info>
  <brief_title>The Endocrine Impact of the Duodenal-jejunal Bypass Sleeve on Type 2 Diabetes - Potential Role of the Incretin Hormones</brief_title>
  <official_title>The Endocrine Impact of the Duodenal-jejunal Bypass Sleeve on Type 2 Diabetes - Potential Role of the Incretin Hormones</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Filip Krag Knop</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We want to evaluate the impact of the EndoBarrier Gastrointestinal Liner (DJBS) on glucose
      metabolism as well as gut and pancreatic hormone secretion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Duodenal-jejunal bypass sleeve (DJBS) is being developed for the treatment of obesity, and
      initial clinical outcomes suggest that this minimally invasive endoscopic technique
      potentially has beneficial effects on type 2 diabetes also. However, the mechanisms behind
      the antidiabetic effects of the procedure remain unknown. We want to elucidate how the DJBS
      might change postprandial secretion of gut and pancreatic hormones.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in postprandial glucagon-like peptide-1 (GLP-1) secretion from baseline 1 week after implantation</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240 minutes</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in postprandial glucagon-like peptide-1 (GLP-1) secretion from baseline 26 weeks after implantation</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240 minutes</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in postprandial glucagon-like peptide-1 (GLP-1) secretion from baseline 52 weeks after implantation</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240 minutes</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in postprandial glucagon-like peptide-1 (GLP-1) secretion from baseline 3 weeks after explantation</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in basal metabolic rate from baseline 1 week after implantation</measure>
    <time_frame>0, 50, 210 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in basal metabolic rate from baseline 26 weeks after implantation</measure>
    <time_frame>0, 50, 210 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in basal metabolic rate from baseline 52 weeks after implantation</measure>
    <time_frame>0, 50, 210 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in basal metabolic rate from baseline 3 weeks after explantation</measure>
    <time_frame>0, 50, 210 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gastric emptying from baseline 1 week after implantation</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gastric emptying from baseline 26 weeks after implantation</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gastric emptying from baseline 52 weeks after implantation</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gastric emptying from baseline 3 weeks after explantation</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gallbladder emptying from baseline 1 week after implantation</measure>
    <time_frame>0, 20, 40, 60, 90, 120, 150, 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gallbladder emptying from baseline 26 weeks after implantation</measure>
    <time_frame>0, 20, 40, 60, 90, 120, 150, 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gallbladder emptying from baseline 52 weeks after implantation</measure>
    <time_frame>0, 20, 40, 60, 90, 120, 150, 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gallbladder emptying from baseline 3 weeks after explantation</measure>
    <time_frame>0, 20, 40, 60, 90, 120, 150, 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in satiety scores as measured by Visual Analogue Scales 1 week after implantation</measure>
    <time_frame>0, 30, 60, 90, 120, 180, 240</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in satiety scores as measured by Visual Analogue Scales 26 weeks after implantation</measure>
    <time_frame>0, 30, 60, 90, 120, 180, 240</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in satiety scores as measured by Visual Analogue Scales 52 weeks after implantation</measure>
    <time_frame>0, 30, 60, 90, 120, 180, 240</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in satiety scores as measured by Visual Analogue Scales 3 weeks after explantation</measure>
    <time_frame>0, 30, 60, 90, 120, 180, 240</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial insulin secretion from baseline 1 week after implantation</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial insulin secretion from baseline 26 weeks after implantation</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial insulin secretion from baseline 52 weeks after implantation</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial insulin secretion from baseline 3 weeks after explantation</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial glucagon secretion 1 week after implantation</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial glucagon secretion 26 weeks after implantation</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial glucagon secretion 52 weeks after implantation</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial glucagon secretion 3 weeks after explantation</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial glucose from baseline 1 week after implantation</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial glucose from baseline 26 weeks after implantation</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial glucose from baseline 52 weeks after implantation</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial glucose form baseline 3 weeks after explantation</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial PYY from baseline 1 week after implantation</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial PYY from baseline 26 weeks after implantation</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial PYY from baseline 52 weeks after implantation</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial PYY from baseline 3 weeks after explantation</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial ghrelin from baseline 1 week after implantation</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial ghrelin from baseline 26 weeks after implantation</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial ghrelin from baseline 52 weeks after implantation</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial ghrelin from baseline 3 weeks after explantation</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial glucosedependent insulinotropic peptide (GIP) from baseline 1 week after implantation</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial glucosedependent insulinotropic peptide (GIP) from baseline 26 weeks after implantation</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial glucosedependent insulinotropic peptide (GIP) from baseline 52 weeks after implantation</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial glucosedependent insulinotropic peptide (GIP) from baseline 3 weeks after explantation</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240 minutes</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in gut microbiota as measured by DNA sequencing from baseline</measure>
    <time_frame>52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in body composition from baseline 26 weeks after implantation</measure>
    <time_frame>1</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in body composition from baseline 52 weeks after implantation</measure>
    <time_frame>1</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in caloric intake as measured by ad libitum meal test 1 week after implantation</measure>
    <time_frame>30 minutes</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in caloric intake as measured by ad libitum meal test 26 weeks after implantation</measure>
    <time_frame>30 minutes</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in caloric intake as measured by ad libitum meal test 52 weeks after implantation</measure>
    <time_frame>30 minutes</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in caloric intake as measured by ad libitum meal test 3 weeks after explantation</measure>
    <time_frame>30 minutes</time_frame>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">25</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Non-diabetic subjects</arm_group_label>
    <description>Obese (BMI &gt; 30 kg/m2) with normal glucose tolerance implanted with the EndoBarrier Gastrointestinal liner</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2DM subjects</arm_group_label>
    <description>Obese (BMI &gt; 30 kg/m2) with type 2 diabetes implanted with the EndoBarrier Gastrointestinal liner</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EndoBarrier Gastrointestinal Liner</intervention_name>
    <description>Implantation with the EndoBarrier</description>
    <arm_group_label>Non-diabetic subjects</arm_group_label>
    <arm_group_label>T2DM subjects</arm_group_label>
    <other_name>DJBS</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood feces
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Obese subjects with or without type 2 diabetes treated with the DJBS will be suitable for
        participating in the trial
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria (obese subjects with type 2 diabetes):

          -  treatment with DJBS

          -  written informed consent

          -  antidiabetic monotherapy/or diet

          -  &gt; 18 years old

          -  not anemic

        Exclusion Criteria (obese subjects with type 2 diabetes):

          -  antidiabetic treatment with insulin, GLP-1-agonists, DPP4-inhibitors or more than one
             orally administered antidiabetic drug.

          -  anemia

        Inclusion Criteria (obese subjects without type 2 diabetes):

          -  Treatment with DJBS

          -  written informed consent

          -  not anemic

          -  HbA1c &lt; 6,0% or HbA1c &lt; 6,5% and normal glucose tolerance test and normal fasting
             plasma glucose (&lt; 6,0 mM)

        Exclusion Criteria (obese subjects without type 2 diabetes):

          -  HbA1c &gt; 6,5 % and/or a non-normal glucose tolerance test and/or fasting plasma glucose
             &gt; 6,0 mM
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filip K Knop, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Diabetes Research, Gentofte Hospital, University of Copenhagen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulrich Rohde, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Diabetes Research, Gentofte Hospital, University of Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Diabetes Research, Gentofte Hospital, University of Copenhagen</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2015</study_first_submitted>
  <study_first_submitted_qc>February 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2015</study_first_posted>
  <last_update_submitted>August 8, 2017</last_update_submitted>
  <last_update_submitted_qc>August 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Filip Krag Knop</investigator_full_name>
    <investigator_title>MD, Ph.D.</investigator_title>
  </responsible_party>
  <keyword>DJBS</keyword>
  <keyword>Duodenal-jejunal bypass sleeve</keyword>
  <keyword>Duodenal-jejunal bypass liner</keyword>
  <keyword>Endobarrier</keyword>
  <keyword>Obesity</keyword>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Incretin hormones</keyword>
  <keyword>Postprandial glucose metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
    <mesh_term>Incretins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

